Nalidixic Acid

Specifications

389-08-2CAS Number

206-864-7EC Number

1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acidIUPAC Name

C12H12N2O3Chemical Formula

232.23 g/molMolecular Weight

nalidixic acid; 389-08-2; Nalidixin; NegGram; Nevigramon; Nalidixan; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Nalurin; Naxuril; Nogram; Urisal; Nalix; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Betaxina; Specifin; Urodixin; Negram; Uralgin; Uriben; Uriclar; Uroneg; Acide nalidixique; Acido nalidixico; Acide nalidixico; NSC-82174; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; WIN 18,320; Acidum nalidixicum; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NCI-C56199; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; WIN-18320; Win 18320; DTXSID3020912; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 3B91HWA56M; CHEBI:100147; NSC82174; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; DTXCID70912; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; Acid, Nalidixic; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-(1,8)naphthyridine-3-carboxylic acid; Neg Gram; Sodium Nalidixic Acid, Anhydrous; RefChem:55688; Anhydrous, Nalidixate Sodium; J01MB02; 206-864-7; Nalidixate; Uronidix; Innoxalon; Nalitucsan; Unaserus; Sicmylon; Cybis; Dixinal; Jicsron; Uroman; Kusnarin; Nalidicron; Nicelate; Narigix; Poleon; Uropan; Specifen; Eucistin; Nalidixane; MFCD00006884; Nalidixic acid (NegGram); MLS000028504; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; NCGC00018181-08; SMR000058264; Wintron; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Acido nalidissico; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; Eucisten; Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; CAS-389-08-2; NegGram (TN); CCRIS 2365; HSDB 3241; EINECS 206-864-7; BRN 0750515; UNII-3B91HWA56M; Innoxalomn; nalidixic-acid; Nalidixanum;; Wintomylon;; SR-01000003086; Negram;; Cybis;; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; NALIDIXICACID; WIN 183203; CHEMBL5; Spectrum_000918; Nalidixic acid [USAN:USP:INN:BAN:JAN]; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; Nalidixic acid (Standard); Epitope ID:613449; Nalidixic acid, >=98%; UPCMLD-DP129; NALIDIXIC ACID [MI]; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; NALIDIXIC ACID [INN]; NALIDIXIC ACID [JAN]; 5-25-07-00384 (Beilstein Handbook Reference); MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; NALIDIXIC ACID [HSDB]; NALIDIXIC ACID [USAN]; SPECTRUM1500756; SPBio_001579; SPBio_002034; NALIDIXIC ACID [VANDF]; BPBio1_000125; orb1225132; orb1710668; orb3025294; NALIDIXIC ACID [MART.]; NALIDIXIC ACID [WHO-DD]; SCHEMBL29367723; UPCMLD-DP129:001; BDBM21691; GTPL12773; HMS500C20; HMS561K17; HY-B0398R; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; MSK5735; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; HMS5080P10; Pharmakon1600-01500756; Nalidixic acid (JP18/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; MSK5735-1000DM; Tox21_110835; Tox21_201477; Tox21_302754; CCG-39298; EBC-04219; MSK5735-100M; NALIDIXIC ACID [EP IMPURITY]; NALIDIXIC ACID [ORANGE BOOK]; NSC757432; SBB002146; STK735579; NALIDIXIC ACID [USP IMPURITY]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; AN16320; DB00779; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AS-13289; NCI60_041807; SMR004703506; SY049448; WLN: T66 BN EV JNJ B2 DVQ I1; Nalidixic acid 100 microg/mL in Methanol; SBI-0050814.P003; DB-049349; Nalidixic acid 100 |Ig/mL in Acetonitrile; Nalidixic acid 1000 microg/mL in Methanol; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; N0490; NS00009829; S2328; SW219624-1; T0909; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; EN300-20573; Nalidixic acid 100 microg/mL in Acetonitrile; VU0239598-6; C05079; D00183; D91720; Nalidixic acid Solution in Methanol, 100ug/mL; Nalidixic acid, meets USP testing specifications; F358268; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-001-21-4; BRD-K47886988-001-22-2; BRD-K47886988-323-03-0; Nalidixic acid Solution in DMSO/Methanol, 1000ug/mL; SR-01000003086-10; F0850-6751; Z104478940; 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid; 1-ETHYL-7-METHYL-4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID; InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17Synonyms